Related Experiment Videos
Biological properties of a CD4 immunoadhesin
R A Byrn1, J Mordenti, C Lucas
1Genentech Inc., South San Francisco, California 94080.
Nature
|April 12, 1990
Summary
CD4 immunoadhesins, engineered proteins targeting HIV, can eliminate infected cells via antibody-dependent cell-mediated cytotoxicity (ADCC) and cross the placenta. These findings suggest potential for preventing mother-to-child HIV transmission.
Area of Science:
- Immunology
- Virology
- Biotechnology
Background:
- Human immunodeficiency virus (HIV) targets CD4 receptors on host cells.
- Recombinant soluble CD4 and CD4 immunoadhesins are being explored as therapeutic agents.
- CD4 immunoadhesins combine CD4's HIV-binding with IgG's pharmacokinetic properties.
Purpose of the Study:
- To investigate the potential of CD4 immunoadhesins in mediating antibody-dependent cell-mediated cytotoxicity (ADCC) against HIV-infected cells.
- To assess the placental transfer efficiency of CD4 immunoadhesins.
- To evaluate the therapeutic implications of CD4 immunoadhesins for preventing perinatal HIV transmission.
Main Methods:
- Construction and characterization of CD4 immunoadhesins.
- Assessment of ADCC activity against HIV-infected cells in vitro.
- Evaluation of ADCC against uninfected cells with bound gp120.
- Primate model studies for placental transfer.
Main Results:
- CD4 immunoadhesins effectively mediated ADCC against HIV-infected cells.
- Unlike natural antibodies, CD4 immunoadhesins did not mediate ADCC against uninfected cells coated with soluble gp120.
- CD4 immunoadhesins demonstrated efficient transfer across the primate placenta.
Conclusions:
- CD4 immunoadhesins possess therapeutic potential for HIV treatment by mediating ADCC.
- The specific ADCC profile and placental transfer suggest a role in preventing mother-to-child HIV transmission.
- Further research into CD4 immunoadhesins could lead to novel strategies for HIV prevention and therapy.